Mme Docteur CARINE DUFAURET-LOMBARD

Bibliographie

• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

  2021

  ArticleThe Lancet Rheumatology

• Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

  2020

  ArticleAnnals of the Rheumatic Diseases

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• CABINET DU DR CARINE DUFAURET-LOMBARD

  1 AVENUE FOULD, 65000 Tarbes

  Libéral
  73 m100 m110 m111 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia

  European journal of pain (London, England) · 2011

  📚 25 citations🎯 RCR 1.02🩺 Clinique

  Lire l'abstract Crossref ↓

  AbstractObjective: The purpose of the study was to evaluate the efficacy and safety of dolasetron for symptomatic relief of pain associated with fibromyalgia (FM).Methods: This prospective, double‐blind, placebo‐controlled trial randomly assigned 60 patients with FM to receive placebo (n =31) or dolasetron (n =29) 12.5 mg/d via the intravenous route on 4 days at baseline (M0), 1 month (M1), 2 months (M2) and 3 months (M3) with follow‐up to month 12. The primary outcome variable was the reduction in pain intensity measured by visual analogue scale (VAS) between M0 and M3. The secondary outcome variables were patient global impression of change (PGIC), the FM impact questionnaire, assessment of quality of life (SF‐36), the hospital anxiety and depression scale, the manual tender point count, and functional symptoms associated with FM.Results: Reduction in pain intensity at M3 was significantly greater in dolasetron‐treated patients (p =0.04, −21.3 on a 0–100 scale) compared with placebo controls (−5.9). More patients in the dolasetron group had ≥30% and ≥50% improvement in pain (42.5% and 28% respectively in the dolasetron group versus 25% and 16% in the placebo group). The PGIC was significantly greater in the dolasetron group at M3 (p =0.02). The other secondary outcomes failed to reach statistical significance. The most common adverse events were constipation, nausea, dizziness and headache, with no significant differences between the two groups.Conclusion: Intermittent IV dolasetron was safe and efficacious for the reduction of pain intensity associated with FM at 3 months.

• 2

  Ultrasonography in chondrocalcinosis

  Joint bone spine · 2010

  📚 17 citations
• 3

  [What are the cardiovascular complications of the analgesics and glucocorticoids?]

  Presse medicale (Paris, France : 1983) · 2006

  📚 2 citations

Publications scientifiques (5) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche